Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study

MA Stokman*, FM Wachters, P Koopmans, JGM Burgerhof, HJM Groen, FKL Spijkervet, DRA Uges, GAP Hospers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)

Abstract

Background: Intravenous administration of amifostine reduces chemotherapy-induced toxicity. Preclinical experiments showed a reduction in radiation-induced mucositis after local application of the active metabolite of amifostine (WR-1065). This study evaluated the effect of local application of WR-1065 on chemotherapy-induced oral mucositis. Patients and Methods: Non-small cell lung cancer patients treated with gemcitabine and epirubicin every 3 weeks for a maximum of five cycles were included. WR-1065 was administered during the second and third cycle as an oral rinse. Oral mucositis evaluation included WHO toxicity grading, a validated oral mucositis assessment scale (OMAS) and a questionnaire. Results: Twenty-four patients were evaluated for at least one control and one rinse cycle. Mucositis scores, pain and feeding difficulties increased from day 1 to day 15, and were not significantly different between the control and rinse cycles. Local application of WR-1065 leads to detectable quantities of WR-1065 in epithelial mucosa cells. A negative correlation between the WR-1065 concentration and OMAS score was found. Conclusion: No clinical detectable influence of WR-1065 on oral mucositis was found.

Original languageEnglish
Pages (from-to)3263-3267
Number of pages5
JournalAnticancer Research
Volume24
Issue number5B
Publication statusPublished - 2004

Keywords

  • CELL LUNG-CANCER
  • ADVANCED HEAD
  • WR-2721
  • CHEMOTHERAPY
  • TRIAL
  • RADIOTHERAPY
  • CISPLATIN
  • PHARMACOKINETICS
  • GEMCITABINE
  • RADIATION

Cite this